Latest Regulatory Filings News

EVE Health Group’s subsidiary Nextract has inked a pivotal two-year agreement with TeleDocs Clinic, enabling nationwide online prescribing of its upcoming erectile dysfunction and dysmenorrhea products ahead of regulatory approval.

Dimerix has reached a key milestone by dosing 200 adult patients in its Phase 3 ACTION3 trial for FSGS, progressing steadily toward full recruitment expected in late 2025.

EVE Health Group has completed its acquisition of Nextract Pty Ltd, positioning itself to enter the lucrative erectile dysfunction and dysmenorrhea markets with innovative drug delivery technologies.

Lindian Resources has secured a combined $1.65 million cash inflow from the exercise of unlisted options and a government R&D tax refund, strengthening its financial position for advancing the Kangankunde Rare Earths Project.

Telix Pharmaceuticals showcased its global theranostic radiopharmaceutical portfolio, highlighting FDA approvals, clinical progress, and a robust commercial expansion plan at its 2025 Investor Day.

Vinyl Group Ltd has had its trading suspension lifted following a Federal Court decision related to its previous non-compliance with cleansing notice requirements.

Optiscan Imaging Ltd has launched InSpecta™, a cutting-edge microscopic imaging device tailored for veterinary medicine, marking its strategic entry into a booming $12 billion US market. The device promises to revolutionize diagnostics and treatment for companion animals with real-time, non-invasive imaging.

Vinyl Group has applied to the Federal Court for an extension to lodge delayed cleansing notices, aiming to lift its ASX trading suspension. The court hearing is set for 5 June 2025, with market watchers awaiting the outcome.

High-Tech Metals Limited has successfully completed a modest capital raise through a non-renounceable entitlement offer, issuing shares at $0.15 each alongside free attaching options. The company now holds discretion over a significant shortfall placement, which could influence its capital structure in the coming months.

Recce Pharmaceuticals has completed a A$15.8 million capital raise to fund pivotal Phase 3 clinical trials and progress its FDA application, positioning the company for potential commercial breakthroughs in antibiotic-resistant infections.

Neurotech International has reported positive human pharmacokinetic results for NTI164, a cannabinoid formulation designed for paediatric neurological disorders, confirming rapid absorption and a non-intoxicating profile.

EVE Health Group has initiated stability testing for its novel oral treatments targeting erectile dysfunction and dysmenorrhea, marking a crucial step toward regulatory approval in Australia. The company also finalizes its acquisition of Nextract, the developer behind these innovative formulations.